Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.56, No.5, p.398-403, 2009 |
||
Title: Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors. | ||
Author: M. MEGO, K. REJLEKOVA, M. RECKOVA, Z. SYCOVA-MILA, J. OBERTOVA, J. RAJEC, J. MARDIAK | ||
Abstract: Early serum tumor marker decline (STMD) during chemotherapy was shown to predict survival in patients with poor prognosis non-seminomatous germ cell tumors (GCT) in the first line. The aim of the study was to assess the prognostic value of STMD in relapsed GCT`s patients. From January 1995 to December 2007, all patients treated for GCT´s with salvage therapy at the National Cancer Institute of Slovakia were identified from the tumor registry database and screened retrospectively for serum AFP and βHCG level at the time of relapse. STMD rate was calculated for each patient and each tumor marker with an abnormal marker value at baseline and each tumor marker M (HCG or AFP) using only two values: the baseline value (M0) and the value obtained after one cycle of chemotherapy (day 21 value; M1). The decline rate was calculated using a logarithmic transformation, and it was expressed as a theoretical number of weeks necessary to normalization that was called predicted time to normalization. Decline rates were classified into „favorable“ or „unfavorable“. Totally, 75 patients were identified, 39 had favourable (group A) and 36 unfavorable (group B) STMD. The 2-year and 5-year PFS rates were 61% and 58% for group A and 17% and 7% group B (p less than 0.00001). Simillary, the 2-year and 5-year OS rates were 79% and 68% for group A and 24% and 16% for group B (p less than 0.00001). Of all the baseline characteristics that were included in the Cox model, STMD was the most important predictor of PFS and OS. We suggest that STMD is strong independent prognostic factor in GCT patients treated with salvage chemotherapy. Prospective studies of different approaches in this patient`s population based on STMD are warranted. |
||
Keywords: germ cell cancer; salvage chemotherapy; serum tumor marker decline | ||
Year: 2009, Volume: 56, Issue: 5 | Page From: 398, Page To: 403 | |
doi:10.4149/neo_2009_05_398 |
||
|
download file |
|